# EDGAR Filing Document

**Accession Number:** 0001119774
**File Stem:** 0001178913-26-000987
**Filing Date:** 2026-3
**Character Count:** 6708
**Document Hash:** cb63e691dc48f8d3c417dc13de0f3e33
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-26-000987.hdr.sgml**: 20260415

**ACCESSION NUMBER**: 0001178913-26-000987

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260318

**DATE AS OF CHANGE**: 20260318

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Levine Zurit
- **CENTRAL INDEX KEY:** 0001972527

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-30902
- **FILM NUMBER:** 26764817

**MAIL ADDRESS:**
- **STREET 1:** 47 HISTADRUT ST.
- **CITY:** HERZLIYA
- **STATE:** L3
- **ZIP:** 46420
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** COMPUGEN LTD
- **CENTRAL INDEX KEY:** 0001119774
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 26 HAROKMIM STREET
- **STREET 2:** BUILDING D
- **CITY:** HOLON
- **STATE:** L3
- **ZIP:** 5885849
- **BUSINESS PHONE:** 011-972-3-765-8585

**MAIL ADDRESS:**
- **STREET 1:** 26 HAROKMIM STREET
- **STREET 2:** BUILDING D
- **CITY:** HOLON
- **STATE:** L3
- **ZIP:** 5885849

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Levine Zurit<br><sub>(Last) (First) (Middle)</sub><br>C/O COMPUGEN LTD.<br>26 HAROKMIM STREET<br><sub>(Street)</sub><br>HOLON,  5885849<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>COMPUGEN LTD [ CGEN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_SVP, Business Development_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 29375<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Share Option (right to buy) | <sup>(2)</sup> | 2026-08-01 | Ordinary Shares | 42000 | $6.65 | D |  |
| Share Option (right to buy) | <sup>(2)</sup> | 2027-08-30 | Ordinary Shares | 31000 | $2.85 | D |  |
| Share Option (right to buy) | <sup>(2)</sup> | 2028-07-31 | Ordinary Shares | 42000 | $3.15 | D |  |
| Share Option (right to buy) | <sup>(2)</sup> | 2029-03-19 | Ordinary Shares | 40000 | $3.80 | D |  |
| Share Option (right to buy) | <sup>(2)</sup> | 2029-08-01 | Ordinary Shares | 40000 | $3.24 | D |  |
| Share Option (right to buy) | <sup>(2)</sup> | 2030-07-29 | Ordinary Shares | 45000 | $14.40 | D |  |
| Share Option (right to buy) | <sup>(2)</sup> | 2031-07-27 | Ordinary Shares | 50000 | $6.45 | D |  |
| Share Option (right to buy) | <sup>(3)</sup> | 2032-03-24 | Ordinary Shares | 60000 | $3.24 | D |  |
| Share Option (right to buy) | <sup>(4)</sup> | 2032-11-09 | Ordinary Shares | 28000 | $0.8292 | D |  |
| Share Option (right to buy) | <sup>(5)</sup> | 2033-08-03 | Ordinary Shares | 60000 | $1.15 | D |  |
| Share Option (right to buy) | <sup>(6)</sup> | 2034-07-31 | Ordinary Shares | 42250 | $1.69 | D |  |
| Share Option (right to buy) | <sup>(7)</sup> | 2035-08-05 | Ordinary Shares | 24000 | $1.46 | D |  |

---

### Footnotes:

(1) Includes 25,821 restricted stock units ("RSUs"). 7,821 RSUs vest in 11 equal quarterly installments commencing on March 31, 2026; and 18,000 RSUs vest 25% on September 30, 2026 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

(2) Fully vested.

(3) This option vested 25% on March 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

(4) This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

(5) This option vested 25% on September 30, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

(6) This option vested 25% on September 30, 2025 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

(7) This option vests 25% on September 30, 2026 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

**Signature:** /s/ Zurit Levine  
**Date:** 2026-03-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**